Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$23.29

0.77 (3.42%)

14:30
06/18/17
06/18
14:30
06/18/17
14:30

Juno Therapeutics reports data from 'TRANSCEND' trial of JCAR017

Juno Therapeutics presented data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B cell non-Hodgkin lymphoma at the International Conference on Malignant Lymphoma. "High rates of durable responses and the early survival data are especially exciting, as is the emerging safety profile. The majority of TRANSCEND patients experienced no cytokine release syndrome or neurotoxicity at all. While still early, these data suggest that JCAR017 could be administered on an outpatient basis," the company remarked. Data for the DLBCL cohort were presented in two groups, core and full. The core analysis group includes patients that represent the population that Juno plans to move forward into a pivotal trial in the second half of 2017. For the core group, findings include: Overall response rate is 86% and the complete response is 59%. Three-month ORR is 66% and CR is 50%. Of patients in response at three months, 90% continue in response at six months. Early data suggest a dose response relationship at three months. 97% of responding patients are alive and in follow-up as of May 4. 2% experienced severe CRS and 18% experienced severe NT. 66% did not experience any CRS or NT. No deaths were reported from CRS or NT. There was one Grade 5 adverse event of diffuse alveolar damage, which the investigator assessed as possibly related to fludarabine, cyclophosphamide, and JCAR017 treatment, occurring on day 23 in an 82-year-old subject who refused mechanical ventilation for progressive respiratory failure while neutropenic on growth factors and broad spectrum antibiotics and antifungals. This patient had no CRS and Grade 3 neurotoxicity resolution before the Grade 5 event. Regarding manufacturing Juno stated: "Product was available for 98% of patients apheresed... Juno expects commercial production will be accomplished in less than 21 days, and Juno is investing in manufacturing infrastructure to enable a smooth prescribing experience with a reliable delivery time at market entry."

  • 19

    Jun

JUNO Juno Therapeutics
$23.29

0.77 (3.42%)

06/08/17
06/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Juno Therapeutics (JUNO) downgraded to Sell from Neutral at BTIG with analyst Dane Leone saying that the company's treatment for CD19 and hematologic malignancies is on track to hit the market later than competing products, while there is no "demonstrated proof" that Juno will have any advantages in the areas of efficacy or toxicity. 2. National Grid (NGG) downgraded to Sell from Hold at Deutsche Bank with analyst James Brand saying the company's sustainable equity cash flow yield could drop below 6% after its next regulatory review. 3. BHP Billiton (BHP) downgraded to Hold from Buy at Jefferies with analyst Christopher LaFemina saying he believes the balance sheet recap trade in mining as well as the Chinese stimulus-driven recovery in demand is over. 4. Lear (LEA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he expects Lear's earnings to peak this year and to fall by 20% by 2021 and expects Electrical business margins to disappoint investors due to higher development costs, increased competition, and potential lost market share. 5. Hawaiian Holdings (HA) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying the valuation is near full following the recent rally. The analyst raised his price target for the shares to $64 from $63. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/17
BTIG
06/08/17
DOWNGRADE
BTIG
Sell
Juno downgraded on lateness to market, lack of differentiation at BTIG
As noted earlier, BTIG downgraded Juno to Sell from Neutral. Analyst Dane Leone says that the company's treatment for CD19 and hematologic malignancies is on track to hit the market later than competing products, while there is no "demonstrated proof" that Juno will have any advantages in the areas of efficacy or toxicity. The analyst expects the revenue generated by Juno's JCAR017 treatment to come in about $1B below consensus expectations through 2026. Target $12.
06/08/17
06/08/17
UPGRADE
Target $100

Buy
Kite Pharma upgraded to Buy on Axi-Cel manufacturing edge at BTIG
As previously reported, BTIG analyst Dane Leone upgraded Kite Pharma (KITE) to Buy from Neutral and set a $100 price target on the shares. Data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers, he tells investors. The analyst sees Kite having the cleanest pathway to approval for diffuse large B-cell lymphoma and, given Kite's manufacturing edge, he estimates that Axi-Cel can take about 60% of share within the U.S. DLBCL market.
06/08/17
BTIG
06/08/17
DOWNGRADE
BTIG
Sell
Juno Therapeutics downgraded to Sell from Neutral at BTIG

TODAY'S FREE FLY STORIES

10:35
09/26/17
09/26
10:35
09/26/17
10:35
General news
U.S. consumer confidence slipped to 119.8 »

U.S. consumer confidence…

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

10:34
09/26/17
09/26
10:34
09/26/17
10:34
Downgrade
Cardtronics rating change  »

Cardtronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.48

-0.03 (-0.08%)

10:30
09/26/17
09/26
10:30
09/26/17
10:30
Options
Bullish option flow in Pfizer »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

  • 08

    Nov

10:30
09/26/17
09/26
10:30
09/26/17
10:30
General news
U.S. Richmond Fed's manufacturing index rose to 19 in September »

U.S. Richmond Fed's…

NSRGY

Nestle

$83.75

0.88 (1.06%)

, VZ

Verizon

$49.83

-0.075 (-0.15%)

10:29
09/26/17
09/26
10:29
09/26/17
10:29
Hot Stocks
Nestle sets new profit targets, though stance on L'Oreal stake unchanged »

Shares of Nestle (NSRGY)…

NSRGY

Nestle

$83.75

0.88 (1.06%)

VZ

Verizon

$49.83

-0.075 (-0.15%)

LRLCY

L'Oreal

$43.13

-0.19 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 19

    Oct

RGEN

Repligen

$43.22

-0.54 (-1.23%)

, GE

General Electric

$25.09

-0.025 (-0.10%)

10:28
09/26/17
09/26
10:28
09/26/17
10:28
Recommendations
Repligen, General Electric analyst commentary  »

GE launch to weight on…

RGEN

Repligen

$43.22

-0.54 (-1.23%)

GE

General Electric

$25.09

-0.025 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 02

    Oct

  • 30

    Nov

ADDYY

adidas

$113.80

-1.22 (-1.06%)

, NKE

Nike

$53.21

-0.025 (-0.05%)

10:28
09/26/17
09/26
10:28
09/26/17
10:28
Periodicals
Adidas, Nike employees reportedly named in FBI corruption probe »

The head of sports…

ADDYY

adidas

$113.80

-1.22 (-1.06%)

NKE

Nike

$53.21

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

CCL

Carnival

$65.80

2.3 (3.62%)

10:27
09/26/17
09/26
10:27
09/26/17
10:27
Hot Stocks
Carnival says booking volumes for 2018 ahead of prior year »

Says Booking volumes for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

10:25
09/26/17
09/26
10:25
09/26/17
10:25
General news
The 3.4% August U.S. new home sales drop »

The 3.4% August U.S. new…

X

U.S. Steel

$24.36

0.305 (1.27%)

10:21
09/26/17
09/26
10:21
09/26/17
10:21
Periodicals
U.S. Steel spokesperson tells Bloomberg company has not sold Slovak unit »

Bloomberg cites U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$24.36

0.305 (1.27%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Periodicals
Chinese company nearing acquisition of U.S. Steel's Kosice, Spectator reports »

The sale of U. S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$70.44

0.1 (0.14%)

, LLEX

Lilis Energy

$4.44

0.09 (2.07%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

DWDP

DowDuPont

$70.44

0.1 (0.14%)

LLEX

Lilis Energy

$4.44

0.09 (2.07%)

ALDR

Alder Biopharmaceuticals

$11.15

0.3 (2.77%)

CORI

Corium

$10.88

0.03 (0.28%)

TGNA

Tegna

$12.92

0.06 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

JPM

JPMorgan

$93.84

-0.28 (-0.30%)

, PNC

PNC Financial

$132.62

-0.905 (-0.68%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

JPM

JPMorgan

$93.84

-0.28 (-0.30%)

PNC

PNC Financial

$132.62

-0.905 (-0.68%)

AFL

Aflac

$83.23

-1.03 (-1.22%)

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

CAKE

Cheesecake Factory

$41.60

0.08 (0.19%)

SHAK

Shake Shack

$31.60

-2.015 (-6.00%)

HABT

Habit Restaurants

GNCA

Genocea

$5.33

0.04 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Sep

  • 02

    Oct

  • 12

    Oct

  • 13

    Oct

  • 22

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

DISCA

Discovery

$21.35

-0.06 (-0.28%)

, MO

Altria Group

$64.87

1.08 (1.69%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

DISCA

Discovery

$21.35

-0.06 (-0.28%)

MO

Altria Group

$64.87

1.08 (1.69%)

LB

L Brands

$42.77

1.87 (4.57%)

SAM

Boston Beer

$159.25

6.25 (4.09%)

BTI

British American Tobacco

$62.01

0.02 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

NKE

Nike

$53.28

0.05 (0.09%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20
Options
Nike option volume heavy pre-earnings with shares flat near $53.16 »

Nike option volume heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

10:20
09/26/17
09/26
10:20
09/26/17
10:20
General news
U.S. consumer confidence dipped 0.6 points to 119.8 in September »

U.S. consumer confidence…

CCL

Carnival

$65.92

2.4185 (3.81%)

, AAPL

Apple

$150.55

-1.34 (-0.88%)

10:18
09/26/17
09/26
10:18
09/26/17
10:18
Hot Stocks
Carnival to launch digital streaming channel Ocean View »

Continues to project cash…

CCL

Carnival

$65.92

2.4185 (3.81%)

AAPL

Apple

$150.55

-1.34 (-0.88%)

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

10:17
09/26/17
09/26
10:17
09/26/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFO

IHS Markit

$48.29

-0.14 (-0.29%)

10:16
09/26/17
09/26
10:16
09/26/17
10:16
Technical Analysis
Technical View: IHS Markit drops after results and outlook »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

$NYE

NYSE Market Internals

10:16
09/26/17
09/26
10:16
09/26/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
09/26/17
09/26
10:15
09/26/17
10:15
General news
Treasury Action: yields stalled below highs »

Treasury Action: yields…

10:15
09/26/17
09/26
10:15
09/26/17
10:15
General news
Breaking General news story  »

Federal Reserve Governor…

SBH

Sally Beauty

$19.74

0.06 (0.30%)

10:13
09/26/17
09/26
10:13
09/26/17
10:13
Conference/Events
Sally Beauty management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

PTCT

PTC Therapeutics

$19.51

0.99 (5.35%)

10:12
09/26/17
09/26
10:12
09/26/17
10:12
Recommendations
PTC Therapeutics analyst commentary  »

PTC briefing documents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 24

    Oct

GOOGL

Alphabet Class A

$934.28

-8.98 (-0.95%)

, GOOG

Alphabet

$920.97

-7.56 (-0.81%)

10:11
09/26/17
09/26
10:11
09/26/17
10:11
Periodicals
Alphabet to split off Google shopping unit to meet EU demands, Bloomberg says »

The new unit will be…

GOOGL

Alphabet Class A

$934.28

-8.98 (-0.95%)

GOOG

Alphabet

$920.97

-7.56 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.